{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:50:43Z","timestamp":1666007443516},"reference-count":24,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2019.11043","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T08:18:45Z","timestamp":1572855525000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report"],"prefix":"10.3892","author":[{"given":"Nobumichi","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ina Central Hospital, Ina, Nagano 396\u20118555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ina Central Hospital, Ina, Nagano 396\u20118555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonomi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ina Central Hospital, Ina, Nagano 396\u20118555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Ina Central Hospital, Ina, Nagano 396\u20118555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"key20200714092338_b1-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"key20200714092338_b2-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20200714092338_b3-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200714092338_b4-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, Phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20200714092338_b5-ol-0-0-11043","first-page":"S1","article-title":"Chronic obstructive pulmonary disease: National clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care","volume":"59","author":"National Collaborating Centre for Chronic Conditions","year":"2004","journal-title":"Thorax"},{"key":"key20200714092338_b6-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"key":"key20200714092338_b7-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1634\/theoncologist.2018-0072","article-title":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: Results of the large, single-arm, open-label phase IIIb CONSIGN study","volume":"24","author":"Van Cutsem","year":"2019","journal-title":"Oncologist"},{"key":"key20200714092338_b8-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/sajc.sajc_173_18","article-title":"Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in metastatic colorectal cancer-an Indian Exploratory analysis study","volume":"8","author":"Ramaswamy","year":"2019","journal-title":"South Asian J Cancer"},{"key":"key20200714092338_b9-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): A randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20200714092338_b10-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New reponse evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Euro J Cancer"},{"key":"key20200714092338_b11-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: Analysis of the CORRECT Japanese and non-Japanese subpopulations","volume":"33","author":"Yoshino","year":"2015","journal-title":"Invest New Drugs"},{"key":"key20200714092338_b12-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"e000111","DOI":"10.1136\/esmoopen-2016-000111","article-title":"Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: Post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)","volume":"1","author":"Ricotta","year":"2017","journal-title":"ESMO Open"},{"key":"key20200714092338_b13-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1102\/1470-7330.2012.0027","article-title":"Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab","volume":"12","author":"Nishino","year":"2012","journal-title":"Cancer Imaging"},{"key":"key20200714092338_b14-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"W1060","DOI":"10.2214\/AJR.11.6459","article-title":"CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab","volume":"197","author":"Boonsirikamchai","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"key20200714092338_b15-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"e0145004","DOI":"10.1371\/journal.pone.0145004","article-title":"Clinical implication of anti-angiogenic effect of regorafenib in metastatic colorectal cancer","volume":"10","author":"Lim","year":"2015","journal-title":"PLoS One"},{"key":"key20200714092338_b16-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bmj.2.4785.639","article-title":"Lymphangitis carcinomatosa","volume":"2","author":"Chandler","year":"1952","journal-title":"Br Med J"},{"key":"key20200714092338_b17-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1503\/cmaj.080142","article-title":"Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult","volume":"179","author":"Thomas","year":"2008","journal-title":"CMAJ"},{"key":"key20200714092338_b18-ol-0-0-11043","first-page":"7","article-title":"Lymphangitis carcinomatosa: A literature review","volume":"41","author":"Bruce","year":"1996","journal-title":"J R Coll Surg Edinb"},{"key":"key20200714092338_b19-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"e76009","DOI":"10.1371\/journal.pone.0076009","article-title":"Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation","volume":"8","author":"Cyran","year":"2013","journal-title":"PLoS One"},{"key":"key20200714092338_b20-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"key20200714092338_b21-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1158\/0008-5472.CAN-04-4576","article-title":"Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels","volume":"65","author":"He","year":"2005","journal-title":"Cancer Res"},{"key":"key20200714092338_b22-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1349-7006.2004.tb03211.x","article-title":"Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer","volume":"95","author":"Shimizu","year":"2004","journal-title":"Cancer Sci"},{"key":"key20200714092338_b23-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.clcc.2018.11.002","article-title":"Third- or later-line therapy for metastatic colorectal cancer: Reviewing best practice","volume":"18","author":"Bekaii-Saab","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"key20200714092338_b24-ol-0-0-11043","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/annonc\/mdt056","article-title":"Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: Results of a multicenter, phase Ib study","volume":"24","author":"Schultheis","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:58:57Z","timestamp":1594720737000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2019.11043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":24,"URL":"https:\/\/doi.org\/10.3892\/ol.2019.11043","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]}}}